Kura Oncology/$KURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
Ticker
$KURA
Sector
Primary listing
Employees
260
Headquarters
Website
Kura Oncology Metrics
BasicAdvanced
$781M
-
-$3.18
0.22
-
Price and volume
Market cap
$781M
Beta
0.22
52-week high
$12.49
52-week low
$5.41
Average daily volume
1.6M
Financial strength
Current ratio
6.058
Quick ratio
5.812
Long term debt to equity
11.014
Total debt to equity
11.748
Interest coverage (TTM)
-200.81%
Profitability
EBITDA (TTM)
-302.599
Gross margin (TTM)
-272.15%
Net profit margin (TTM)
-412.95%
Operating margin (TTM)
-449.94%
Effective tax rate (TTM)
-0.11%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-25.33%
Return on equity (TTM)
-94.82%
Valuation
Price to revenue (TTM)
11.485
Price to book
4.46
Price to tangible book (TTM)
4.46
Price to free cash flow (TTM)
-10.963
Free cash flow yield (TTM)
-9.12%
Free cash flow per share (TTM)
-0.806
Growth
Revenue change (TTM)
25.24%
Earnings per share change (TTM)
57.40%
3-year earnings per share growth (CAGR)
16.16%
10-year earnings per share growth (CAGR)
3.39%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $781M as of March 13, 2026.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of March 13, 2026.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.